Short Interest in Masimo Corporation (NASDAQ:MASI) Decreases By 30.0%

Masimo Corporation (NASDAQ:MASI) saw a significant decrease in short interest in the month of March. As of March 13th, there was short interest totaling 2,680,885 shares, a decrease of 30.0% from the February 26th total of 3,828,135 shares. Currently, 6.0% of the company’s stock are short sold. Based on an average daily trading volume, of 1,848,469 shares, the short-interest ratio is currently 1.5 days.

Masimo Stock Up 0.1%

MASI stock traded up $0.22 on Friday, hitting $177.11. 1,134,695 shares of the company’s stock were exchanged, compared to its average volume of 1,976,752. Masimo has a 12-month low of $125.94 and a 12-month high of $179.00. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.47 and a current ratio of 2.49. The stock has a market cap of $9.51 billion, a P/E ratio of -16.80, a price-to-earnings-growth ratio of 1.79 and a beta of 1.21. The firm has a 50 day moving average price of $159.93 and a two-hundred day moving average price of $148.32.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC purchased a new stake in shares of Masimo during the fourth quarter valued at $27,000. Aster Capital Management DIFC Ltd purchased a new position in Masimo in the 4th quarter worth $28,000. Los Angeles Capital Management LLC acquired a new stake in Masimo during the 4th quarter worth about $31,000. MAI Capital Management lifted its position in Masimo by 176.7% during the 2nd quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 129 shares during the period. Finally, Rothschild Investment LLC grew its stake in Masimo by 12,950.0% during the 4th quarter. Rothschild Investment LLC now owns 261 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 259 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analyst Upgrades and Downgrades

MASI has been the topic of several recent research reports. Wells Fargo & Company raised Masimo to a “hold” rating in a research report on Wednesday, March 18th. Piper Sandler cut Masimo from an “overweight” rating to a “hold” rating and set a $180.00 price objective for the company. in a research note on Tuesday, February 17th. Raymond James Financial downgraded Masimo from an “outperform” rating to a “market perform” rating in a research report on Friday. BTIG Research lowered Masimo from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 18th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Monday, December 1st. Eight investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $181.17.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company specializing in noninvasive monitoring solutions. The company’s flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo’s portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.